This study focuses on patients with malignant solid tumors, including breast cancer, endometrial cancer, ovarian cancer, and squamous non-small-cell lung cancer. The research examines a new medication called GEN1047, which is given as a solution for infusion directly into the vein. This is the first time this medication is being tested in humans.
The main purpose of this research is to find the safest and most effective dose of GEN1047 for treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to determine the most appropriate amount. In the second part, the chosen dose will be given to more patients to better understand how well it works against these types of cancer.
During the study, patients will receive GEN1047 through intravenous administration. The treatment will be given in cycles, and doctors will regularly monitor patients’ health and how their cancer responds to the treatment. They will track any side effects and measure how the medication moves through the body. Patients will undergo regular medical examinations and imaging tests to assess their response to the treatment.
Belgium 
Denmark 
France 
Italy 
Poland 
Spain 
The Netherlands 
